
Eton Pharmaceuticals, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Eton Pharmaceuticals develops and markets pharmaceutical products for rare diseases and other conditions with limited treatment options, focusing on reformulations such as oral liquids and ready-to-use injectables of existing drugs.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Krempa DavidChief Business Officer | Sell | $229K | 4,166at $55.07 | Oct 6, 2026 |
| BRYNJELSEN SEANPresident & CEO | Sell | $2.85M | 47,307at $60.17 | Aug 20, 2026 |
| BRYNJELSEN SEANPresident & CEO | Sell | $2.22M | 36,373at $61.11 | Aug 20, 2026 |
| BRYNJELSEN SEANPresident & CEO | Sell | $562K | 8,978at $62.65 | Aug 19, 2026 |
| BRYNJELSEN SEANPresident & CEO | Sell | $456K | 7,342at $62.12 | Aug 20, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable ETON activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.